This point is embodied in our study that combinational inhibition of KRAS and NF-κB improved immunogenicity of tumor cells, recruiting effector T cells and thus synergized with PD-1 inhibitors to shrink KRAS mutation positive lung cancer of low ZNF24 expression. The gene discussed is KRAS; the disease is lung carcinoma.